Infiltrating breast carcinoma in patients age 30 years and younger: Long term outcome for life, relapse, and second primary tumors

Catherine G. Lee, Beryl McCormick, Madhuchhanda Mazumdar, John Vetto, Patrick I. Borgen

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

A retrospective study examining the influence of young age, defined as 30 years or less on the outcome of early-staged (American Joint Committee 19784, II) breast cancer was undertaken using patients treated between 1950 and 1970 to ensure a long follow-up period. Because of the era of treatment, radical mastectomy without systemic chemotherapy was the predominant treatment. Ninety-nine patients met study criteria, with a median follow-up of 11.4 years (range 0.5 to 41 years). The patient group was compared to patients of all ages, treated at Memorial Sloan-Kettering Cancer Center in 1960 (5 and 10 years) and to patients treated between 1940 and 1943 (30 year follow-up). At the 5, 10, and 30 year follow-up periods, patients in the young age group consistently had disease-specific survival 10-20% lower than their older counterparts. For young patients who survived their first cancer diagnosis, second primaries both in the contralateral breast and elsewhere, played a significant role in determining their subsequent life span. When compared to risks of second primary cancers in the National Cancer Institute's SEER (Surveillance, Epidemiology and End Results Program) Cancer Registry for all ages, the increased risk for very young breast cancer patients was significant (p = 0.000). With these two findings in mind, treatment for young patients with breast cancer should focus not on local therapy options alone but on the increased risk of both systemic disease and of second primaries.

Original languageEnglish (US)
Pages (from-to)969-975
Number of pages7
JournalInternational journal of radiation oncology, biology, physics
Volume23
Issue number5
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

breast
tumors
cancer
Breast Neoplasms
Recurrence
Neoplasms
Second Primary Neoplasms
SEER Program
epidemiology
Radical Mastectomy
life span
National Cancer Institute (U.S.)
Therapeutics
chemotherapy
surveillance
Registries
therapy
Breast
Retrospective Studies
Age Groups

Keywords

  • Infiltrating breast cancer
  • Mastectomy
  • Young age group

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Infiltrating breast carcinoma in patients age 30 years and younger : Long term outcome for life, relapse, and second primary tumors. / Lee, Catherine G.; McCormick, Beryl; Mazumdar, Madhuchhanda; Vetto, John; Borgen, Patrick I.

In: International journal of radiation oncology, biology, physics, Vol. 23, No. 5, 1992, p. 969-975.

Research output: Contribution to journalArticle

@article{a0ff7e5e10cf4fb987b9765739d68108,
title = "Infiltrating breast carcinoma in patients age 30 years and younger: Long term outcome for life, relapse, and second primary tumors",
abstract = "A retrospective study examining the influence of young age, defined as 30 years or less on the outcome of early-staged (American Joint Committee 19784, II) breast cancer was undertaken using patients treated between 1950 and 1970 to ensure a long follow-up period. Because of the era of treatment, radical mastectomy without systemic chemotherapy was the predominant treatment. Ninety-nine patients met study criteria, with a median follow-up of 11.4 years (range 0.5 to 41 years). The patient group was compared to patients of all ages, treated at Memorial Sloan-Kettering Cancer Center in 1960 (5 and 10 years) and to patients treated between 1940 and 1943 (30 year follow-up). At the 5, 10, and 30 year follow-up periods, patients in the young age group consistently had disease-specific survival 10-20{\%} lower than their older counterparts. For young patients who survived their first cancer diagnosis, second primaries both in the contralateral breast and elsewhere, played a significant role in determining their subsequent life span. When compared to risks of second primary cancers in the National Cancer Institute's SEER (Surveillance, Epidemiology and End Results Program) Cancer Registry for all ages, the increased risk for very young breast cancer patients was significant (p = 0.000). With these two findings in mind, treatment for young patients with breast cancer should focus not on local therapy options alone but on the increased risk of both systemic disease and of second primaries.",
keywords = "Infiltrating breast cancer, Mastectomy, Young age group",
author = "Lee, {Catherine G.} and Beryl McCormick and Madhuchhanda Mazumdar and John Vetto and Borgen, {Patrick I.}",
year = "1992",
doi = "10.1016/0360-3016(92)90901-S",
language = "English (US)",
volume = "23",
pages = "969--975",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Infiltrating breast carcinoma in patients age 30 years and younger

T2 - Long term outcome for life, relapse, and second primary tumors

AU - Lee, Catherine G.

AU - McCormick, Beryl

AU - Mazumdar, Madhuchhanda

AU - Vetto, John

AU - Borgen, Patrick I.

PY - 1992

Y1 - 1992

N2 - A retrospective study examining the influence of young age, defined as 30 years or less on the outcome of early-staged (American Joint Committee 19784, II) breast cancer was undertaken using patients treated between 1950 and 1970 to ensure a long follow-up period. Because of the era of treatment, radical mastectomy without systemic chemotherapy was the predominant treatment. Ninety-nine patients met study criteria, with a median follow-up of 11.4 years (range 0.5 to 41 years). The patient group was compared to patients of all ages, treated at Memorial Sloan-Kettering Cancer Center in 1960 (5 and 10 years) and to patients treated between 1940 and 1943 (30 year follow-up). At the 5, 10, and 30 year follow-up periods, patients in the young age group consistently had disease-specific survival 10-20% lower than their older counterparts. For young patients who survived their first cancer diagnosis, second primaries both in the contralateral breast and elsewhere, played a significant role in determining their subsequent life span. When compared to risks of second primary cancers in the National Cancer Institute's SEER (Surveillance, Epidemiology and End Results Program) Cancer Registry for all ages, the increased risk for very young breast cancer patients was significant (p = 0.000). With these two findings in mind, treatment for young patients with breast cancer should focus not on local therapy options alone but on the increased risk of both systemic disease and of second primaries.

AB - A retrospective study examining the influence of young age, defined as 30 years or less on the outcome of early-staged (American Joint Committee 19784, II) breast cancer was undertaken using patients treated between 1950 and 1970 to ensure a long follow-up period. Because of the era of treatment, radical mastectomy without systemic chemotherapy was the predominant treatment. Ninety-nine patients met study criteria, with a median follow-up of 11.4 years (range 0.5 to 41 years). The patient group was compared to patients of all ages, treated at Memorial Sloan-Kettering Cancer Center in 1960 (5 and 10 years) and to patients treated between 1940 and 1943 (30 year follow-up). At the 5, 10, and 30 year follow-up periods, patients in the young age group consistently had disease-specific survival 10-20% lower than their older counterparts. For young patients who survived their first cancer diagnosis, second primaries both in the contralateral breast and elsewhere, played a significant role in determining their subsequent life span. When compared to risks of second primary cancers in the National Cancer Institute's SEER (Surveillance, Epidemiology and End Results Program) Cancer Registry for all ages, the increased risk for very young breast cancer patients was significant (p = 0.000). With these two findings in mind, treatment for young patients with breast cancer should focus not on local therapy options alone but on the increased risk of both systemic disease and of second primaries.

KW - Infiltrating breast cancer

KW - Mastectomy

KW - Young age group

UR - http://www.scopus.com/inward/record.url?scp=0026703821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026703821&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(92)90901-S

DO - 10.1016/0360-3016(92)90901-S

M3 - Article

C2 - 1322389

AN - SCOPUS:0026703821

VL - 23

SP - 969

EP - 975

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -